ES2149182T3 - Anticuerpo recombinante dirigido contra el calicivirus felino y fragmentos de genes de este anticuerpo. - Google Patents

Anticuerpo recombinante dirigido contra el calicivirus felino y fragmentos de genes de este anticuerpo.

Info

Publication number
ES2149182T3
ES2149182T3 ES93103066T ES93103066T ES2149182T3 ES 2149182 T3 ES2149182 T3 ES 2149182T3 ES 93103066 T ES93103066 T ES 93103066T ES 93103066 T ES93103066 T ES 93103066T ES 2149182 T3 ES2149182 T3 ES 2149182T3
Authority
ES
Spain
Prior art keywords
antibody
fcv
feline
recombinant
feline calicivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93103066T
Other languages
English (en)
Inventor
Kazuhiko Kimachi
Hiroaki Maeda
Kiyoto Nishiyama
Sachio Tokiyoshi
Yukinobu Tohya
Takeshi Mikami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Application granted granted Critical
Publication of ES2149182T3 publication Critical patent/ES2149182T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UN ANTICUERPO RECOMBINANTE DE TIPO FELINO ANTI-FCV (CALICIVIRUS FELINO) EFECTIVO PARA TRATAMIENTO, PREVENCION Y DIAGNOSIS DEL FCV Y UN FRAGMENTO DE GEN UTIL PARA LA PREPARACION DE DICHO ANTICUERPO. SE HA CONSTRUIDO LA LINEA CELULAR 1D7 CAPAZ DE PRODUCIR UN ANTICUERPO MONOCLONAL DE RATON QUE TIENE UNA EXCELENTE ACTIVIDAD NEUTRALIZADORA DEL FCV ASI COMO UN FRAGMENTO DE GEN QUE CODIFICA LA REGION V EN LA CARGA DE LA UNION ESPECIFICA AL FCV DE DICHO ANTICUERPO. EL FRAGMENTO DE GEN Y EL GEN DE CODIFICA LA REGION CONSTANTE DEL ANTICUERPO FELINO SE USAN PARA DAR COMO RESULTADO UN ANTICUERPO RECOMBINANTE QUIMERICO ANTI-FCV. EL ANTICUERPO RECOMBINANTE OBTENIDO ES UN NUEVO ANTICUERPO QUE ES UTIL PARA LA DIAGNOSIS, TRATAMIENTO Y PREVENCION DE LAS INFECCIONES POR EL VIRUS FELINO ESPECIALMENTE POR EL CALICIVIRUS FELINO, CON UNA ALTA SEGURIDAD EN SU ADMINISTRACION A LOS GATOS.
ES93103066T 1992-02-28 1993-02-26 Anticuerpo recombinante dirigido contra el calicivirus felino y fragmentos de genes de este anticuerpo. Expired - Lifetime ES2149182T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7918992 1992-02-28

Publications (1)

Publication Number Publication Date
ES2149182T3 true ES2149182T3 (es) 2000-11-01

Family

ID=13683035

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93103066T Expired - Lifetime ES2149182T3 (es) 1992-02-28 1993-02-26 Anticuerpo recombinante dirigido contra el calicivirus felino y fragmentos de genes de este anticuerpo.

Country Status (7)

Country Link
US (1) US5785968A (es)
EP (1) EP0561194B1 (es)
AT (1) ATE193725T1 (es)
AU (1) AU661106B2 (es)
CA (1) CA2090515C (es)
DE (1) DE69328799T2 (es)
ES (1) ES2149182T3 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083390A2 (en) * 2003-03-14 2004-09-30 Regents Of The University Of California Virulent systemic feline calicivirus
US7309495B2 (en) * 2003-03-14 2007-12-18 The Regents Of The University Of California Hemorrhagic feline calicivirus
DE102011118031B4 (de) 2011-06-23 2013-08-01 Technische Universität Dresden Calicivirus bindende Peptide, dafür kodierende Nukleinsäuren, deren Verwendungen und Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Caliciviren
US9901478B2 (en) 2014-03-11 2018-02-27 Chine, Llc Methods and apparatuses for the external distraction in the assistance of spinal deformities
CN115141273B (zh) * 2022-06-21 2024-02-06 泰州博莱得利生物科技有限公司 一种猫杯状病毒的单克隆抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937812A (en) * 1974-11-21 1976-02-10 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US3944469A (en) * 1974-11-21 1976-03-16 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH01309785A (ja) 1988-06-06 1989-12-14 Babcock Hitachi Kk ミドルパルスｔｉｇ溶接装置
ATE119545T1 (de) * 1989-07-21 1995-03-15 Upjohn Co Felincalicivirus-capsid-protein und nukleotidsequenz.
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin

Also Published As

Publication number Publication date
CA2090515A1 (en) 1993-08-29
DE69328799D1 (de) 2000-07-13
DE69328799T2 (de) 2000-10-26
EP0561194A3 (en) 1994-08-24
ATE193725T1 (de) 2000-06-15
US5785968A (en) 1998-07-28
AU661106B2 (en) 1995-07-13
CA2090515C (en) 2002-10-29
EP0561194B1 (en) 2000-06-07
EP0561194A2 (en) 1993-09-22
AU3391193A (en) 1993-09-02

Similar Documents

Publication Publication Date Title
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
BR112022002202A2 (pt) Métodos de tratar doença de fabry em pacientes tendo uma mutação no gene gla
ES2032194T3 (es) Solubilizacion de agregados proteicos.
DK1786A (da) Apparat til medicinsk behandling med udladninger for bipolare elektroder
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ES2149182T3 (es) Anticuerpo recombinante dirigido contra el calicivirus felino y fragmentos de genes de este anticuerpo.
Hoyos-Calderon et al. Myofascial trigger points and central sensitization signs, but no anxiety, are shown in women with dysmenorrhea: A case-control study
García et al. Exploring the contrasts and similarities of dengue and SARS-CoV-2 infections during the COVID-19 era
Pajic et al. High-frequency deep sclerotomy, a minimal invasive Ab interno glaucoma procedure combined with cataract surgery: Physical properties and clinical outcome
Granese et al. Effects of SARS-CoV-2 vaccination on menstrual cycle: An Italian survey-based study
ATE309361T1 (de) Nukleinsaure-molekul umfassend eine fur ein sdf-1 gamma chemokin,einen neuropeptid-prakursor oder mindestens ein neuropeptid kodierende nukleinsauresequenz
Komori et al. Energy spectrum of cosmic-ray muons
Breese Jr et al. Electron microscopy of African swine fever virus hemadsorption
Bankovskii et al. Physical processes of image formation during gas-discharge visualization (the Kirlian effect)
ES2102675T3 (es) Virus obtenible de celulas de neuroblastoma humanas.
Lambert et al. A study of vital rates near a nuclear reactor
Wargo Interaction of stress and secondary organisms in decline of forest trees.
Pennock Comment on Sartori's Review (Vol. 74, December 1980, pp. 1060–61)
Particle Accelerator Div Depth absorbed dose distributions for electrons
Sur et al. Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition
Jokisch et al. Damage to DNA Resulting from Ionizing Radiation
Westmore Coronavirus: China must answer hard questions
Golubnichii et al. Radiation trigger for the seismically active layer in detectors of high-energy neutrino beams
Okada Toxicologic screening in Japan
McElhaney Health-funding boost not enough for Canada

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 561194

Country of ref document: ES